1 INTRODUCTION 36
1.1 STUDY OBJECTIVES 36
1.2 MARKET DEFINITION 36
1.2.1 INCLUSIONS AND EXCLUSIONS 37
1.3 STUDY SCOPE 38
1.3.1 MOLECULAR DIAGNOSTICS MARKET: MARKET SEGMENTATION 38
1.3.2 MOLECULAR DIAGNOSTICS MARKET: GEOGRAPHICAL SEGMENTATION 39
1.3.3 YEARS CONSIDERED 39
1.4 CURRENCY CONSIDERED 40
1.5 MARKET LIMITATIONS 40
1.6 STAKEHOLDERS 41
1.7 SUMMARY OF CHANGES 41
2 RESEARCH METHODOLOGY 42
2.1 RESEARCH DATA 42
2.2 RESEARCH APPROACH 42
FIGURE 1 MOLECULAR DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY 42
2.2.1 SECONDARY DATA 43
2.2.1.1 Key data from secondary sources 43
2.2.2 PRIMARY DATA 44
2.2.2.1 Primary sources 45
2.2.2.2 Key data from primary sources 45
2.2.2.3 Key industry insights 46
2.2.2.4 Breakdown of primary interviews 47
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS 47
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 47
2.3 MARKET SIZE ESTIMATION 48
2.3.1 BOTTOM-UP APPROACH 48
2.3.1.1 Approach 1: Company revenue estimation approach 49
FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 49
2.3.1.2 Approach 2: Company presentations and primary interviews 49
2.3.1.3 Growth forecast 49
2.3.1.4 CAGR projections 50
FIGURE 5 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS 50
2.3.2 TOP-DOWN APPROACH 50
FIGURE 6 MOLECULAR DIAGNOSTICS MARKET: TOP-DOWN APPROACH 51
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 52
FIGURE 7 DATA TRIANGULATION METHODOLOGY 52
2.5 MARKET SHARE ANALYSIS 52
2.6 STUDY ASSUMPTIONS 53
2.7 RESEARCH LIMITATIONS 53
2.8 GROWTH RATE ASSUMPTIONS 54
2.9 RISK ASSESSMENT 54
2.9.1 RISK ASSESSMENT OF MOLECULAR DIAGNOSTICS MARKET 54
2.10 IMPACT OF ECONOMIC RECESSION ON MOLECULAR DIAGNOSTICS MARKET 54
3 EXECUTIVE SUMMARY 57
FIGURE 8 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION) 57
FIGURE 9 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023 VS. 2028 (USD MILLION) 58
FIGURE 10 MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023 VS. 2028 (USD MILLION) 58
FIGURE 11 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION) 59
FIGURE 12 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 60
FIGURE 13 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 60
FIGURE 14 MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2023 VS. 2028 (USD MILLION) 61
4 PREMIUM INSIGHTS 63
4.1 MOLECULAR DIAGNOSTICS MARKET OVERVIEW 63
FIGURE 15 INCREASING PREVALENCE OF INFECTIOUS DISEASES AND RISING INCIDENCE OF CANCER TO SUPPORT MARKET 63
4.2 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 64
FIGURE 16 REAGENTS & KITS TO DOMINATE MOLECULAR DIAGNOSTICS MARKET IN 2028 64
4.3 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023 VS. 2028 64
FIGURE 17 LAB TESTS TO COMMAND GREATER MARKET SHARE IN 2028 64
4.4 MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023 VS. 2028 65
FIGURE 18 BLOOD, SERUM, AND PLASMA SEGMENT TO DOMINATE MARKET DURING STUDY PERIOD 65
4.5 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023 VS. 2028 65
FIGURE 19 PCR SEGMENT TO DOMINATE MOLECULAR DIAGNOSTICS MARKET DURING FORECAST PERIOD 65
4.6 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023 VS. 2028 66
FIGURE 20 INFECTIOUS DISEASE DIAGNOSTICS SEGMENT TO DOMINATE MARKET IN 2028 66
4.7 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023 VS. 2028 66
FIGURE 21 DIAGNOSTIC LABORATORIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 66
4.8 MOLECULAR DIAGNOSTICS MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES 67
FIGURE 22 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN MOLECULAR DIAGNOSTICS MARKET DURING STUDY PERIOD 67
5 MARKET OVERVIEW 68
5.1 INTRODUCTION 68
5.2 MARKET DYNAMICS 68
FIGURE 23 MOLECULAR DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 68
5.2.1 DRIVERS 69
5.2.1.1 Increasing prevalence of infectious diseases and cancer globally 69
TABLE 1 ESTIMATED NUMBER OF NEW CANCER CASES GLOBALLY, BY TYPE OF CANCER, 2020 VS. 2025 71
TABLE 2 GLOBAL CANCER INCIDENCE, BY REGION, 2020 VS. 2025 71
5.2.1.2 Rising focus on R&D and growing funding in molecular diagnostics by healthcare-based companies 71
5.2.1.3 Growing awareness regarding early disease diagnosis in developing countries 73
5.2.1.4 Rising technological advancements in molecular diagnostics in recent years 73
5.2.1.5 Increasing use of PoC diagnostic tests in homecare settings and hospitals 74
5.2.2 RESTRAINTS 74
5.2.2.1 Unfavorable reimbursement scenario for diagnostic companies 74
5.2.2.2 High cost of molecular diagnostic instruments 74
5.2.3 OPPORTUNITIES 75
5.2.3.1 Growing significance of companion diagnostics in drug development process 75
5.2.3.2 Increasing growth opportunities for molecular diagnostics companies in emerging economies 75
5.2.4 CHALLENGES 76
5.2.4.1 Changing regulatory landscape for IVD and molecular diagnostics in US and European Union 76
5.2.4.2 Operational barriers and shortage of skills across major markets 76
5.2.4.3 Introduction of alternative technologies for disease detection and diagnosis 76
5.3 PRICING ANALYSIS 77
5.3.1 AVERAGE SELLING PRICE OF MOLECULAR DIAGNOSTICS PRODUCTS, BY KEY PLAYER 77
TABLE 3 AVERAGE SELLING PRICE OF MOLECULAR DIAGNOSTIC PRODUCTS 77
5.4 PATENT ANALYSIS 78
FIGURE 24 PATENT ANALYSIS FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGIES (JANUARY 2013–DECEMBER 2022) 78
5.4.1 LIST OF MAJOR PATENTS 79
5.5 VALUE CHAIN ANALYSIS 80
FIGURE 25 VALUE CHAIN ANALYSIS OF MOLECULAR DIAGNOSTICS MARKET: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES 81
5.6 SUPPLY CHAIN ANALYSIS 82
FIGURE 26 MOLECULAR DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS 82
5.7 ECOSYSTEM/MARKET MAP ANALYSIS 83
FIGURE 27 MOLECULAR DIAGNOSTICS MARKET: ECOSYSTEM/MARKET MAP ANALYSIS 83
5.7.1 MOLECULAR DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM 84
5.8 PORTER’S FIVE FORCES ANALYSIS 84
TABLE 4 MOLECULAR DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 84
5.8.1 THREAT FROM NEW ENTRANTS 85
5.8.2 THREAT FROM SUBSTITUTES 85
5.8.3 BARGAINING POWER OF BUYERS 85
5.8.4 BARGAINING POWER OF SUPPLIERS 85
5.8.5 INTENSITY OF COMPETITIVE RIVALRY 85
5.9 REGULATORY ANALYSIS 86
TABLE 5 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86
TABLE 6 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86
TABLE 7 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87
TABLE 8 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87
5.9.1 NORTH AMERICA 87
5.9.1.1 US 87
5.9.1.2 Canada 87
5.9.2 EUROPE 88
TABLE 9 EUROPE: CLASSIFICATION OF DEVICES 88
5.9.3 ASIA PACIFIC 89
5.9.3.1 China 89
5.9.3.2 Japan 89
TABLE 10 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 89
5.9.3.3 India 89
5.9.4 LATIN AMERICA 90
5.9.4.1 Brazil 90
5.9.4.2 Mexico 90
5.9.5 MIDDLE EAST 90
5.9.6 AFRICA 91
5.10 TRADE ANALYSIS 91
5.10.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS 91
5.10.1.1 Import data for diagnostic and laboratory reagents, by country, 2018–2022 (USD million) 91
5.10.1.2 Export data for diagnostic and laboratory reagents, by country, 2018–2022 (USD million) 91
5.11 TECHNOLOGY ANALYSIS 91
5.12 KEY CONFERENCES AND EVENTS IN 2023–2024 93
TABLE 11 MOLECULAR DIAGNOSTICS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS IN 2023–2024 93
5.13 PESTLE ANALYSIS 95
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 96
5.14.1 REVENUE SHIFT IN MOLECULAR DIAGNOSTICS MARKET 96
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA 96
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS 96
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF MOLECULAR DIAGNOSTIC PRODUCTS 96
TABLE 12 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF MOLECULAR DIAGNOSTIC PRODUCTS (%) 97
5.15.2 BUYING CRITERIA 97
FIGURE 29 KEY BUYING CRITERIA FOR MOLECULAR DIAGNOSTIC PRODUCTS 97
TABLE 13 KEY BUYING CRITERIA FOR MOLECULAR DIAGNOSTIC PRODUCTS 98
5.16 CASE STUDY ANALYSIS 98
FIGURE 30 CASE STUDY: MARKET ASSESSMENT AND CONSUMER BUYING BEHAVIOR IN INDIA 98
6 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE 99
6.1 INTRODUCTION 100
TABLE 14 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 100
TABLE 15 PRICE OF MOLECULAR DIAGNOSTIC PRODUCTS (2022) 100
6.2 REAGENTS & KITS 101
6.2.1 RECURRENT PURCHASES OF REAGENTS & KITS FOR DIAGNOSTIC ANALYSIS TO PROPEL MARKET 101
TABLE 16 MOLECULAR DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY REGION, 2021–2028 (USD MILLION) 102
6.3 INSTRUMENTS 102
6.3.1 INCREASING NEED FOR FASTER AND MORE ACCURATE TEST RESULTS TO BOOST MARKET 102
TABLE 17 KEY INSTRUMENTS AVAILABLE IN GLOBAL MARKET 103
TABLE 18 MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2021–2028 (USD MILLION) 103
6.4 SERVICES & SOFTWARE 104
6.4.1 INCREASING UPTAKE OF ADVANCED INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET TO DRIVE GROWTH 104
TABLE 19 MOLECULAR DIAGNOSTICS MARKET FOR SERVICES & SOFTWARE, BY REGION, 2021–2028 (USD MILLION) 104
7 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE 105
7.1 INTRODUCTION 106
TABLE 20 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2028 (USD MILLION) 106
7.1.1 PRIMARY NOTES 106
7.1.1.1 Key industry insights 106
7.2 LAB TESTS 107
7.2.1 ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES AND INCREASED FOCUS ON EARLY DISEASE DETECTION TO DRIVE MARKET 107
TABLE 21 MOLECULAR DIAGNOSTICS MARKET FOR LAB TESTS, BY REGION, 2021–2028 (USD MILLION) 108
7.3 POC TESTS 108
7.3.1 FASTER TURNAROUND TIME OF POC TESTS TO DRIVE SEGMENT GROWTH 108
TABLE 22 MOLECULAR DIAGNOSTICS MARKET FOR POC TESTS, BY REGION, 2021–2028 (USD MILLION) 109
8 MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE 110
8.1 INTRODUCTION 111
TABLE 23 MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 111
8.2 BLOOD, SERUM, AND PLASMA 111
8.2.1 UTILIZATION OF BLOOD SAMPLES IN DETECTING AND MANAGING INFECTIOUS DISEASES TO DRIVE MARKET 111
TABLE 24 MOLECULAR DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY REGION, 2021–2028 (USD MILLION) 112
8.3 URINE 112
8.3.1 NON-INVASIVE NATURE OF URINE SAMPLES TO FUEL SEGMENT GROWTH 112
TABLE 25 MOLECULAR DIAGNOSTICS MARKET FOR URINE, BY REGION, 2021–2028 (USD MILLION) 113
8.4 OTHER SAMPLE TYPES 113
TABLE 26 MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2021–2028 (USD MILLION) 113
9 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY 114
9.1 INTRODUCTION 115
9.1.1 PRIMARY NOTES 115
9.1.1.1 Key industry insights 115
TABLE 27 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 116
9.2 POLYMERASE CHAIN REACTION 116
9.2.1 GROWING USE OF POLYMERASE CHAIN REACTION IN PROTEOMICS AND GENOMICS TO DRIVE MARKET 116
TABLE 28 MOLECULAR DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2021–2028 (USD MILLION) 117
9.3 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY 117
9.3.1 COST BENEFITS OF ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY IN NUCLEIC ACID SEQUENCING TO DRIVE MARKET 117
TABLE 29 MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2021–2028 (USD MILLION) 118
9.4 DNA SEQUENCING & NEXT-GENERATION SEQUENCING 118
9.4.1 INCREASING USE OF NEXT-GENERATION SEQUENCING IN CANCER DIAGNOSIS TO FUEL MARKET 118
TABLE 30 MOLECULAR DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2021–2028 (USD MILLION) 119
9.5 IN SITU HYBRIDIZATION 120
9.5.1 RISING PREVALENCE OF CANCER AND GENETIC DISORDERS TO DRIVE MARKET 120
TABLE 31 MOLECULAR DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2021–2028 (USD MILLION) 120
9.6 DNA MICROARRAYS 121
9.6.1 INTRODUCTION OF DNA MICROARRAYS TO ACCELERATE GENE EXPRESSION AND DISEASE DIAGNOSIS 121
TABLE 32 MOLECULAR DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY REGION, 2021–2028 (USD MILLION) 121
9.7 OTHER TECHNOLOGIES 122
TABLE 33 MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021–2028 (USD MILLION) 122
10 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION 123
10.1 INTRODUCTION 124
TABLE 34 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 124
10.2 INFECTIOUS DISEASE DIAGNOSTICS 124
TABLE 35 MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY REGION, 2021–2028 (USD MILLION) 125
TABLE 36 MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION) 125
10.2.1 HEPATITIS 126
10.2.1.1 Increasing adoption of advanced technologies for diagnosis of hepatitis B to drive segment 126
TABLE 37 HEPATITIS MARKET, BY REGION, 2021–2028 (USD MILLION) 126
TABLE 38 HEPATITIS MARKET, BY REGION, 2021–2028 (MILLION TESTS) 127
10.2.2 HIV 127
10.2.2.1 Increased global prevalence of HIV to propel segment 127
TABLE 39 HIV MARKET, BY REGION, 2021–2028 (USD MILLION) 127
TABLE 40 HIV MARKET, BY REGION, 2021–2028 (MILLION TESTS) 128
10.2.3 CT/NG 128
10.2.3.1 CT/NG infections to be most common sexually transmitted disease globally 128
TABLE 41 CT/NG MARKET, BY REGION, 2021–2028 (USD MILLION) 129
TABLE 42 CT/NG MARKET, BY REGION, 2021–2028 (MILLION TESTS) 129
10.2.4 HAIS 129
10.2.4.1 Rising burden of MRSA infections and increasing adoption of technologically advanced HAI diagnostic tests to aid market 129
TABLE 43 HAIS MARKET, BY REGION, 2021–2028 (USD MILLION) 130
TABLE 44 HAIS MARKET, BY REGION, 2021–2028 (MILLION TESTS) 130
10.2.5 HPV 131
10.2.5.1 Technological advancements for preventing HPV infections to augment market 131
TABLE 45 HPV MARKET, BY REGION, 2021–2028 (USD MILLION) 131
TABLE 46 HPV MARKET, BY REGION, 2021–2028 (MILLION TESTS) 131
10.2.6 TUBERCULOSIS 132
10.2.6.1 Increasing burden of TB globally to propel market 132
TABLE 47 TUBERCULOSIS MARKET, BY REGION, 2021–2028 (USD MILLION) 132
TABLE 48 TUBERCULOSIS MARKET, BY REGION, 2021–2028 (MILLION TESTS) 133
10.2.7 INFLUENZA 133
10.2.7.1 Rising focus on decreasing spread of influenza to propel segment 133
TABLE 49 INFLUENZA MARKET, BY REGION, 2021–2028 (USD MILLION) 134
TABLE 50 INFLUENZA MARKET, BY REGION, 2021–2028 (MILLION TESTS) 134
10.2.8 OTHER INFECTIOUS DISEASES 134
TABLE 51 OTHER INFECTIOUS DISEASES MARKET, BY REGION, 2021–2028 (USD MILLION) 135
10.3 ONCOLOGY TESTING 135
TABLE 52 MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION) 136
TABLE 53 MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY REGION, 2021–2028 (USD MILLION) 137
10.3.1 BREAST CANCER 137
10.3.1.1 Increasing prevalence of breast cancer among females to boost market 137
TABLE 54 BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2040 137
TABLE 55 BREAST CANCER MARKET, BY REGION, 2021–2028 (USD MILLION) 138
10.3.2 COLORECTAL CANCER 138
10.3.2.1 Rising focus on development of companion diagnostic assays to fuel market 138
TABLE 56 COLORECTAL CANCER MARKET, BY REGION, 2021–2028 (USD MILLION) 138
10.3.3 LUNG CANCER 139
10.3.3.1 Increasing research for lung cancer biomarkers to drive market 139
TABLE 57 LUNG CANCER MARKET, BY REGION, 2021–2028 (USD MILLION) 139
10.3.4 PROSTATE CANCER 139
10.3.4.1 Advancements in genomic technologies for development of new biomarkers to aid market 139
TABLE 58 PROSTATE CANCER MARKET, BY REGION, 2021–2028 (USD MILLION) 140
10.3.5 OTHER CANCERS 140
TABLE 59 GLOBAL CANCER INCIDENCE, 2020 140
TABLE 60 OTHER CANCERS MARKET, BY REGION, 2021–2028 (USD MILLION) 141
10.4 GENETIC TESTING 141
10.4.1 DIAGNOSIS OF VARIOUS DISEASES THROUGH GENETIC TESTING METHODS TO PROPEL MARKET 141
TABLE 61 MOLECULAR DIAGNOSTICS MARKET FOR GENETIC TESTING, BY REGION, 2021–2028 (USD MILLION) 141
10.5 OTHER APPLICATIONS 142
TABLE 62 MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 142
10.6 COVID-19 142
10.6.1 DECLINING CASES OF COVID-19 TO HINDER MARKET 142
TABLE 63 MOLECULAR DIAGNOSTICS MARKET FOR COVID-19, BY REGION, 2021–2028 (USD MILLION) 143
11 MOLECULAR DIAGNOSTICS MARKET, BY END USER 144
11.1 INTRODUCTION 145
TABLE 64 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 145
11.2 DIAGNOSTIC LABORATORIES 145
11.2.1 INCREASED OUTSOURCING OF LABORATORY DIAGNOSES FOR REDUCTION IN COSTS TO DRIVE MARKET 145
TABLE 65 MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2021–2028 (USD MILLION) 146
11.3 HOSPITALS & CLINICS 146
11.3.1 GREATER NUMBER OF HOSPITALS AND HIGHER GOVERNMENT INVESTMENTS IN HEALTHCARE TO BOOST SEGMENT 146
TABLE 66 MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2021–2028 (USD MILLION) 147
11.4 OTHER END USERS 147
TABLE 67 MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION) 148
12 MOLECULAR DIAGNOSTICS MARKET, BY REGION 149
12.1 INTRODUCTION 150
TABLE 68 MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2021–2028 (USD MILLION) 150
12.2 NORTH AMERICA 150
FIGURE 31 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET SNAPSHOT 152
TABLE 69 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 152
TABLE 70 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 153
TABLE 71 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 153
TABLE 72 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 154
TABLE 73 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 154
TABLE 74 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION) 155
TABLE 75 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION) 155
TABLE 76 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 156
12.2.1 IMPACT OF ECONOMIC RECESSION ON NORTH AMERICA 156
12.2.2 US 156
12.2.2.1 Increasing prevalence of infectious diseases and cancer to drive market 156
TABLE 77 US: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 157
TABLE 78 US: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 157
TABLE 79 US: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 158
TABLE 80 US: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION) 158
TABLE 81 US: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION) 159
TABLE 82 US: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 159
12.2.3 CANADA 159
12.2.3.1 High availability of funding for genomics research to fuel market 159
TABLE 83 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 160
TABLE 84 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 160
TABLE 85 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 161
TABLE 86 CANADA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION) 161
TABLE 87 CANADA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION) 162
TABLE 88 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 162
12.3 EUROPE 162
TABLE 89 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 163
TABLE 90 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 163
TABLE 91 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 164
TABLE 92 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 164
TABLE 93 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 165
TABLE 94 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION) 165
TABLE 95 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION) 166
TABLE 96 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 166
12.3.1 IMPACT OF ECONOMIC RECESSION ON EUROPE 166
12.3.2 GERMANY 167
12.3.2.1 Increasing healthcare expenditure with favorable government policies and rising per capita disposable income to propel market 167
TABLE 97 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 167
TABLE 98 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 168
TABLE 99 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 168
TABLE 100 GERMANY: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION) 169
TABLE 101 GERMANY: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION) 169
TABLE 102 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 170
12.3.3 UK 170
12.3.3.1 Growing number of accredited diagnostic laboratories to fuel market 170
TABLE 103 UK: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 171
TABLE 104 UK: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 171
TABLE 105 UK: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 171
TABLE 106 UK: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION) 172
TABLE 107 UK: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION) 172
TABLE 108 UK: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 173
12.3.4 FRANCE 173
12.3.4.1 Rising R&D expenditure and increasing demand for early disease diagnosis to augment market 173
TABLE 109 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 173
TABLE 110 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 174
TABLE 111 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 174
TABLE 112 FRANCE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION) 175
TABLE 113 FRANCE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION) 175
TABLE 114 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 176
12.3.5 ITALY 176
12.3.5.1 Adoption of advanced diagnostic technologies to support market 176
TABLE 115 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 177
TABLE 116 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 177
TABLE 117 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 177
TABLE 118 ITALY: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION) 178
TABLE 119 ITALY: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION) 178
TABLE 120 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 179
12.3.6 SPAIN 179
12.3.6.1 Growing demand for genetic testing to create major growth opportunities for market players 179
TABLE 121 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 180
TABLE 122 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 180
TABLE 123 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 181
TABLE 124 SPAIN: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION) 181
TABLE 125 SPAIN: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION) 182
TABLE 126 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 182
12.3.7 RUSSIA 182
12.3.7.1 Increasing access to quality healthcare and growing incidence of infectious diseases to aid market 182
TABLE 127 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 183
TABLE 128 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 183
TABLE 129 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 184
TABLE 130 RUSSIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION) 184
TABLE 131 RUSSIA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION) 185
TABLE 132 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 185
12.3.8 REST OF EUROPE 185
TABLE 133 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 186
TABLE 134 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 186
TABLE 135 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 187
TABLE 136 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION) 187
TABLE 137 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION) 188
TABLE 138 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 188
12.4 ASIA PACIFIC 188
FIGURE 32 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET SNAPSHOT 189
TABLE 139 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 190
TABLE 140 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 190
TABLE 141 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 190
TABLE 142 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 191
TABLE 143 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 191
TABLE 144 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION) 192
TABLE 145 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION) 192
TABLE 146 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 193
12.4.1 IMPACT OF ECONOMIC RECESSION ON ASIA PACIFIC 193
12.4.2 CHINA 193
12.4.2.1 Rapid economic growth and greater public access to modern healthcare to drive market 193
TABLE 147 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 194
TABLE 148 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 194
TABLE 149 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 195
TABLE 150 CHINA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION) 195
TABLE 151 CHINA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION) 196
TABLE 152 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 196
12.4.3 JAPAN 196
12.4.3.1 Universal healthcare reimbursement policy to support market 196
TABLE 153 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 197
TABLE 154 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 197
TABLE 155 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 198
TABLE 156 JAPAN: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION) 198
TABLE 157 JAPAN: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION) 199
TABLE 158 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 199
12.4.4 INDIA 199
12.4.4.1 Increased private & public investments and large patient population to drive market 199
TABLE 159 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 200
TABLE 160 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 201
TABLE 161 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 201
TABLE 162 INDIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION) 202
TABLE 163 INDIA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION) 202
TABLE 164 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 203
12.4.5 AUSTRALIA 203
12.4.5.1 High prevalence of infectious diseases to fuel market 203
TABLE 165 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 203
TABLE 166 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 204
TABLE 167 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 204
TABLE 168 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION) 205
TABLE 169 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION) 205
TABLE 170 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 206
12.4.6 REST OF ASIA PACIFIC 206
TABLE 171 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 207
TABLE 172 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 207
TABLE 173 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 208
TABLE 174 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION) 208
TABLE 175 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION) 209
TABLE 176 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 209
TABLE 177 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 210
TABLE 178 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 210
TABLE 179 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 210
TABLE 180 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 211
TABLE 181 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 211
TABLE 182 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION) 212
TABLE 183 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION) 212
TABLE 184 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 213
12.5.1 IMPACT OF ECONOMIC RECESSION ON LATIN AMERICA 213
12.5.2 BRAZIL 213
12.5.2.1 Improving healthcare infrastructure and stringent regulations to fuel market 213
TABLE 185 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 214
TABLE 186 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 214
TABLE 187 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 215
TABLE 188 BRAZIL: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION) 215
TABLE 189 BRAZIL: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION) 216
TABLE 190 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 216
12.5.3 MEXICO 216
12.5.3.1 Improving accessibility and affordability of healthcare services to aid market 216
TABLE 191 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 217
TABLE 192 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 217
TABLE 193 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 218
TABLE 194 MEXICO: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION) 218
TABLE 195 MEXICO: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION) 219
TABLE 196 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 219
12.5.4 REST OF LATIN AMERICA 219
TABLE 197 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 220
TABLE 198 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 220
TABLE 199 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 221
TABLE 200 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION) 221
TABLE 201 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION) 222
TABLE 202 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 22
12.6 MIDDLE EAST & AFRICA 222
12.6.1 ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES AND INCREASED HEALTHCARE INVESTMENTS TO PROPEL MARKET 222
TABLE 203 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 223
TABLE 204 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 223
TABLE 205 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 224
TABLE 206 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 224
TABLE 207 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION) 225
TABLE 208 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION) 225
TABLE 209 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 226
12.6.2 IMPACT OF ECONOMIC RECESSION ON MIDDLE EAST & AFRICA 226
13 COMPETITIVE LANDSCAPE 227
13.1 OVERVIEW 227
13.2 STRATEGIES ADOPTED BY KEY PLAYERS 227
13.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN MOLECULAR DIAGNOSTICS MARKET 228
TABLE 210 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MOLECULAR DIAGNOSTIC MANUFACTURING COMPANIES 228
13.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 230
FIGURE 33 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN MOLECULAR DIAGNOSTICS MARKET 230
13.4 MARKET SHARE ANALYSIS 231
FIGURE 34 MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER (2022) 231
TABLE 211 MOLECULAR DIAGNOSTICS MARKET: DEGREE OF COMPETITION 231
13.4.1 MOLECULAR DIAGNOSTICS MARKET SHARE AND RANKING ANALYSIS, BY TECHNOLOGY 233
13.4.1.1 Polymerase chain reaction (PCR) 233
FIGURE 35 GLOBAL MOLECULAR DIAGNOSTICS MARKET SHARE FOR PCR, BY KEY PLAYER (2022) 233
13.4.1.2 DNA sequencing and NGS 233
FIGURE 36 GLOBAL MOLECULAR DIAGNOSTICS MARKET SHARE FOR DNA SEQUENCING & NGS, BY KEY PLAYER (2022) 233
13.4.1.3 Isothermal nucleic acid amplification technology (INAAT) 234
TABLE 212 GLOBAL MOLECULAR DIAGNOSTICS MARKET RANKING FOR INAAT, BY KEY PLAYER, 2022 234
13.4.1.4 In situ hybridization (ISH) 234
TABLE 213 GLOBAL MOLECULAR DIAGNOSTICS MARKET RANKING FOR ISH, BY KEY PLAYER, 2022 234
13.4.2 MOLECULAR DIAGNOSTICS MARKET RANKING ANALYSIS, BY APPLICATION 234
13.4.2.1 Infectious diseases 234
TABLE 214 GLOBAL MOLECULAR DIAGNOSTICS MARKET RANKING FOR INFECTIOUS DISEASES, BY KEY PLAYER, 2022 234
13.5 COMPANY EVALUATION MATRIX FOR KEY PLAYERS 235
13.5.1 LIST OF EVALUATED VENDORS 235
13.5.2 STARS 235
13.5.3 EMERGING LEADERS 235
13.5.4 PERVASIVE PLAYERS 235
13.5.5 PARTICIPANTS 235
FIGURE 37 MOLECULAR DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022 236
13.6 COMPANY EVALUATION MATRIX FOR START-UPS/SMES (2022) 237
13.6.1 PROGRESSIVE COMPANIES 237
13.6.2 STARTING BLOCKS 237
13.6.3 RESPONSIVE COMPANIES 237
13.6.4 DYNAMIC COMPANIES 237
FIGURE 38 MOLECULAR DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022 238
13.7 COMPETITIVE BENCHMARKING 239
13.7.1 PRODUCT AND GEOGRAPHICAL FOOTPRINT ANALYSIS 239
FIGURE 39 PRODUCT AND GEOGRAPHICAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN MOLECULAR DIAGNOSTICS MARKET 239
TABLE 215 MOLECULAR DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS 239
TABLE 216 COMPANY PRODUCT & SERVICE FOOTPRINT 240
TABLE 217 COMPANY REGIONAL FOOTPRINT 240
TABLE 218 MOLECULAR DIAGNOSTICS MARKET: DETAILED LIST OF KEY START-UPS/SMES 240
13.8 COMPETITIVE SCENARIO 241
13.8.1 KEY PRODUCT LAUNCHES 241
TABLE 219 KEY PRODUCT LAUNCHES AND REGULATORY APPROVALS 241
13.8.2 KEY DEALS 242
TABLE 220 KEY DEALS 242
14 COMPANY PROFILES 243
14.1 KEY PLAYERS 243
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
14.1.1 F. HOFFMANN-LA ROCHE LTD. 243
TABLE 221 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 243
FIGURE 40 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022) 244
14.1.2 HOLOGIC, INC. 250
TABLE 222 HOLOGIC, INC.: COMPANY OVERVIEW 250
FIGURE 41 HOLOGIC, INC.: COMPANY SNAPSHOT (2022) 251
14.1.3 ABBOTT LABORATORIES 255
TABLE 223 ABBOTT LABORATORIES: COMPANY OVERVIEW 255
FIGURE 42 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022) 256
14.1.4 BIOMÉRIEUX 260
TABLE 224 BIOMÉRIEUX: COMPANY OVERVIEW 260
FIGURE 43 BIOMÉRIEUX: COMPANY SNAPSHOT (2022) 261
14.1.5 THERMO FISHER SCIENTIFIC INC. 266
TABLE 225 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 266
FIGURE 44 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022) 267
14.1.6 QIAGEN 271
TABLE 226 QIAGEN: COMPANY OVERVIEW 271
FIGURE 45 QIAGEN: COMPANY SNAPSHOT (2022) 272
14.1.7 PERKINELMER INC. 276
TABLE 227 PERKINELMER INC.: COMPANY OVERVIEW 276
FIGURE 46 PERKINELMER INC.: COMPANY SNAPSHOT (2022) 277
14.1.8 MYRIAD GENETICS, INC. 279
TABLE 228 MYRIAD GENETICS, INC.: COMPANY OVERVIEW 279
FIGURE 47 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2022) 280
14.1.9 SIEMENS HEALTHINEERS AG 282
TABLE 229 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 282
FIGURE 48 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022) 283
14.1.10 DANAHER 285
TABLE 230 DANAHER: COMPANY OVERVIEW 285
FIGURE 49 DANAHER: COMPANY SNAPSHOT (2022) 286
14.2 OTHER PLAYERS 289
14.2.1 ILLUMINA, INC. 289
14.2.2 BECTON, DICKINSON AND COMPANY 290
14.2.3 GRIFOLS, S.A. 291
14.2.4 QUIDELORTHO CORPORATION 292
14.2.5 AGILENT TECHNOLOGIES, INC. 293
14.2.6 DIASORIN S.P.A. 295
14.2.7 EXACT SCIENCES CORPORATION 296
14.2.8 GENETIC SIGNATURES 297
14.2.9 MDXHEALTH 298
14.2.10 HTG MOLECULAR DIAGNOSTICS, INC. 299
14.2.11 BIOCARTIS 300
14.2.12 TBG DIAGNOSTICS LIMITED 301
TABLE 231 TBG DIAGNOSTICS LIMITED: COMPANY OVERVIEW 301
14.2.13 VELA DIAGNOSTICS 302
TABLE 232 VELA DIAGNOSTICS: COMPANY OVERVIEW 302
14.2.14 AMOY DIAGNOSTICS CO., LTD. 303
TABLE 233 AMOY DIAGNOSTICS CO., LTD.: COMPANY OVERVIEW 303
14.2.15 ELITECHGROUP 304
TABLE 234 ELITECHGROUP: COMPANY OVERVIEW 304
14.2.16 MOLBIO DIAGNOSTICS PVT. LTD. 306
TABLE 235 MOLBIO DIAGNOSTICS PVT. LTD.: COMPANY OVERVIEW 306
14.2.17 SAVYON DIAGNOSTICS 308
TABLE 236 SAVYON DIAGNOSTICS: COMPANY OVERVIEW 308
14.2.18 ABACUS DIAGNOSTICA OY 309
TABLE 237 ABACUS DIAGNOSTICA OY.: COMPANY OVERVIEW 309
14.2.19 GENEOMBIO TECHNOLOGIES PVT. LTD. 310
TABLE 238 GENEOMBIO TECHNOLOGIES PVT. LTD.: COMPANY OVERVIEW 310
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
15 APPENDIX 311
15.1 DISCUSSION GUIDE 311
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 316
15.3 CUSTOMIZATION OPTIONS 318
15.4 RELATED REPORTS 318
15.5 AUTHOR DETAILS 319
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
